Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

BridgeBio's Attruby surpasses expectations with booming Q1 revenue and strong market positioning. Read why BBIO stock is ...

Many investors love the "big mo." That's short for "big momentum." Stocks that are on a roll often keep the good times going. Keith Speights (Alnylam Pharmaceuticals): In her comments during Alnylam ...